Xifaxan Reduces Risk of 30-Day Rehospitalization After OHE

Bausch Health Companies Inc. reported that Xifaxan (rifaximin) lowers the risk of 30-day rehospitalization for overt hepatic encephalopathy (OHE), as detailed in a recent claims-based analysis. These findings were presented at Digestive Disease Week 2025. The study indicates Xifaxan's efficacy irrespective of the patient's prior treatment history.

Dr. Arun Jesudian highlighted the growing cases of chronic liver disease and the importance of providing optimal treatment to prevent recurrent OHE and reduce the broader healthcare burden. The data shows that patients discharged with lactulose alone face a higher rehospitalization risk compared to those treated with Xifaxan.

Aimee Lenar emphasized the necessity for guideline-based care post-discharge. The analysis utilized data from the Komodo Research Database to assess OHE patient outcomes and found significant influences based on the quality of care received.